Caribou's workforce strategy from 2020 through 2026 has been defined by a pronounced trend of strategic portfolio rationalization and resource reallocation, with significant operational adjustments observed in 2023. This period reflects a deliberate shift away from broader exploratory programs towards a highly concentrated focus on core therapeutic assets. The underlying rationale for these adjustments centers on achieving heightened operational efficiency and accelerating the development timelines for their prioritized CAR-T pipeline. Specifically, the company initiated a targeted workforce reduction in July 2023, impacting 21 positions, as it divested its NK cell therapy program to strategically reallocate capital towards its burgeoning CAR-T priorities. This was subsequently followed by a more substantial cut of 47 roles in October 2023, coinciding with the discontinuation of its lupus program and a specific leukemia CAR-T asset. These decisive actions were explicitly taken to consolidate resources and intensify efforts on two identified lead CAR-T candidates, signaling a clear commitment to maximizing return on investment within its most promising programs. The absence of further data extending into 2026 prevents a comprehensive assessment of future workforce projections or additional strategic shifts beyond the observed 2023 recalibrations.
